QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Article 31 Non-Pharmacovigilance Referrals in EU Medicines Regulation

Test your understanding of the concepts covered by Article 31 Non-Pharmacovigilance Referral in EU Medicines Regulation: Quality, Efficacy and Union-Level Regulatory Assessment.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which conclusion is not justified solely by the existence of an Article 31 non-pharmacovigilance referral?

A defined concern has entered a formal Union-level assessment The concern will be evaluated through the applicable statutory procedure The product has already been demonstrated to be defective The outcome may require action after the assessment

Question 2 of 10 Why should the annexes to a final Commission decision be reviewed during implementation?

They may contain the operative changes to the authorisation or product information They contain only background scientific literature They replace the need to review the legal basis They determine which committee appointed the rapporteur

Question 3 of 10 Which statement correctly characterises expert consultation during a complex referral?

External experts replace CHMP's responsibility for the opinion Expert consultation can provide specialised input while CHMP remains responsible for adopting the scientific opinion Experts may redefine the legal scope without a formal procedure Expert consultation is limited to pharmacovigilance referrals

Question 4 of 10 A quality referral leads to restrictions on use because the product's clinical risk profile changes under certain manufacturing conditions. What should the MAH assess beyond quality-system actions?

Only whether the batch-release procedure was updated Potential pharmacovigilance consequences, including case identification, monitoring and communication needs Whether the referral can be deleted from the product history Whether the issue should be reclassified retrospectively as a PRAC referral

Question 5 of 10 Why should a company's response be mapped question-by-question to evidence and residual uncertainty?

To increase the length of the submission To demonstrate traceability and show how each CHMP question has been addressed To avoid providing data that may be relevant to another question To replace the need for a scientific conclusion

Question 6 of 10 A surrogate endpoint remains statistically significant, but its relationship to patient-important outcomes is uncertain. What should the assessment address?

Only the p-value for the surrogate endpoint The endpoint's validation, magnitude of effect, clinical relevance and consistency with clinical outcomes Whether the study was conducted outside the Union Whether the MAH agrees with the statistical analysis

Question 7 of 10 Which record structure best supports inspection readiness for an Article 31 referral?

A file containing only the final public summary A chronological record linking the initiating concern, referral, questions, responses, opinion, decision and implementation A collection of scientific publications without regulatory documents A correspondence folder organised only by employee name

Question 8 of 10 Several nationally authorised products and one centrally authorised product are potentially affected by the same scientific concern. What is the appropriate first procedural step?

Assume Article 31 applies to all products Assume Article 20 applies because one centrally authorised product is involved Determine the formal product scope and authorisation categories before classifying the referral mechanism Allow each MAH to select the preferred referral route

Question 9 of 10 Which statement best describes regulatory proportionality in the outcome of a non-pharmacovigilance referral?

The least restrictive measure must always be selected Any identified concern requires revocation The measure should reflect the demonstrated concern, uncertainty, legal requirements and ability to control the issue Proportionality applies only to national urgent measures

Question 10 of 10 A later clinical study produces a smaller treatment effect than an earlier pivotal study. What is the most appropriate regulatory interpretation?

The product is proven ineffective The earlier study must be disregarded automatically Confidence in the efficacy conclusion may have weakened, but the integrated evidence must be assessed The matter automatically becomes a pharmacovigilance referral

QPPV.com

Knowledge Assessment: Article 31 Non-Pharmacovigilance Referrals in EU Medicines Regulation

Cookie Settings